Mistry PC - Search Results

1

First administration of the Fc-attenuated anti-β amyloid antibody GSK933776 to patients with mild Alzheimer's disease: a randomized, placebo-controlled study.

Andreasen N, Simeoni M, Ostlund H, Lisjo PI, Fladby T, Loercher AE, Byrne GJ, Murray F, Scott-Stevens PT, Wallin A, Zhang YY, Bronge LH, Zetterberg H, Nordberg AK, Yeo AJ, Khan SA, Hilpert J, Mistry PC. Andreasen N, et al. Among authors: mistry pc. PLoS One. 2015 Mar 19;10(3):e0098153. doi: 10.1371/journal.pone.0098153. eCollection 2015. PLoS One. 2015. PMID: 25789616 Free PMC article. Clinical Trial.

2

Modulation of β-amyloid by a single dose of GSK933776 in patients with mild Alzheimer's disease: a phase I study.

Leyhe T, Andreasen N, Simeoni M, Reich A, von Arnim CA, Tong X, Yeo A, Khan S, Loercher A, Chalker M, Hottenstein C, Zetterberg H, Hilpert J, Mistry P. Leyhe T, et al. Alzheimers Res Ther. 2014 Apr 9;6(2):19. doi: 10.1186/alzrt249. eCollection 2014. Alzheimers Res Ther. 2014. PMID: 24716469 Free PMC article.

3

Pharmacokinetic and Pharmacodynamic Characterisation of an Anti-Mouse TNF Receptor 1 Domain Antibody Formatted for In Vivo Half-Life Extension.

Goodall LJ, Ovecka M, Rycroft D, Friel SL, Sanderson A, Mistry P, Davies ML, Stoop AA. Goodall LJ, et al. PLoS One. 2015 Sep 9;10(9):e0137065. doi: 10.1371/journal.pone.0137065. eCollection 2015. PLoS One. 2015. PMID: 26352810 Free PMC article.

4

A Study to Investigate the Efficacy and Safety of an Anti-Interleukin-18 Monoclonal Antibody in the Treatment of Type 2 Diabetes Mellitus.

McKie EA, Reid JL, Mistry PC, DeWall SL, Abberley L, Ambery PD, Gil-Extremera B. McKie EA, et al. Among authors: mistry pc. PLoS One. 2016 Mar 1;11(3):e0150018. doi: 10.1371/journal.pone.0150018. eCollection 2016. PLoS One. 2016. PMID: 26930607 Free PMC article. Clinical Trial.

5

A multi-center randomized proof-of-concept clinical trial applying [¹⁸F]FDG-PET for evaluation of metabolic therapy with rosiglitazone XR in mild to moderate Alzheimer's disease.

Tzimopoulou S, Cunningham VJ, Nichols TE, Searle G, Bird NP, Mistry P, Dixon IJ, Hallett WA, Whitcher B, Brown AP, Zvartau-Hind M, Lotay N, Lai RY, Castiglia M, Jeter B, Matthews JC, Chen K, Bandy D, Reiman EM, Gold M, Rabiner EA, Matthews PM. Tzimopoulou S, et al. J Alzheimers Dis. 2010;22(4):1241-56. doi: 10.3233/JAD-2010-100939. J Alzheimers Dis. 2010. PMID: 20930300 Clinical Trial.

6

Long-Term Safety and Efficacy of Belimumab in Patients With Systemic Lupus Erythematosus: A Continuation of a Seventy-Six-Week Phase III Parent Study in the United States.

Furie RA, Wallace DJ, Aranow C, Fettiplace J, Wilson B, Mistry P, Roth DA, Gordon D. Furie RA, et al. Arthritis Rheumatol. 2018 Jun;70(6):868-877. doi: 10.1002/art.40439. Epub 2018 Apr 25. Arthritis Rheumatol. 2018. PMID: 29409143 Free PMC article. Clinical Trial.

7

Assessment of the analgesic effect of remifentanil using three pain models in healthy Korean volunteers: a randomized, controlled study.

Kim TE, Kim KP, Shin D, Chung YJ, Price J, Mistry P, Jang IJ, Yu KS. Kim TE, et al. Basic Clin Pharmacol Toxicol. 2012 Jun;110(6):518-23. doi: 10.1111/j.1742-7843.2011.00849.x. Epub 2012 Jan 18. Basic Clin Pharmacol Toxicol. 2012. PMID: 22181006 Free article. Clinical Trial.

8

Selective blockade of tumor necrosis factor receptor I inhibits proinflammatory cytokine and chemokine production in human rheumatoid arthritis synovial membrane cell cultures.

Schmidt EM, Davies M, Mistry P, Green P, Giddins G, Feldmann M, Stoop AA, Brennan FM. Schmidt EM, et al. Arthritis Rheum. 2013 Sep;65(9):2262-73. doi: 10.1002/art.38055. Arthritis Rheum. 2013. PMID: 23784528 Free article.

9

Safety, tolerability, pharmacokinetics, and pharmacodynamics of single-dose antiinterleukin- 18 mAb GSK1070806 in healthy and obese subjects.

Mistry P, Reid J, Pouliquen I, McHugh S, Abberley L, DeWall S, Taylor A, Tong X, Rocha Del Cura M, McKie E. Mistry P, et al. Int J Clin Pharmacol Ther. 2014 Oct;52(10):867-79. doi: 10.5414/CP202087. Int J Clin Pharmacol Ther. 2014. PMID: 25109413 Clinical Trial.

10

Quantifying disease activity in rheumatoid arthritis with the TSPO PET ligand ¹⁸F-GE-180 and comparison with ¹⁸F-FDG and DCE-MRI.

de Groot M, Patel N, Manavaki R, Janiczek RL, Bergstrom M, Östör A, Gerlag D, Roberts A, Graves MJ, Karkera Y, Fernando D, Mistry P, Walker A, Wisniacki N, Fryer TD, Jimenez-Royo P. de Groot M, et al. EJNMMI Res. 2019 Dec 19;9(1):113. doi: 10.1186/s13550-019-0576-8. EJNMMI Res. 2019. PMID: 31858293 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

14 results

Search Page

Filters